Pete Holding
RGN, PgDip, MSc (clinical trials)
NDS Research Nurse / Research Associate
- Median 20-year data collection for the ProtecT trial
- Quantum Biobank - reconsent of a historical cohort (ProtecT)
My research focusses on the management of prostate cancer
Prostate cancer is the most common cancer in men - about 40,000 men are diagnosed annually in the UK. The ProtecT (Prostate testing for cancer and Treatment) trial - is a case-finding and randomised controlled trial of treatment effectiveness - the largest of its kind in the UK. I have been involved in this trial since 1999 - from it's initial pilot-phase and then throughout the main trial recruitment and follow up phases.
My current role is to collect the data for the median 20-year analysis. In addition to this, I'm helping to ensure that samples collected from participants recruited onto the ProtecT trial have enduring consent and thus continue to be a resource for basic and translational research. The work ultimately aims to provide future patients diagnosed with prostate cancer the knowledge to determine to best treatment for them.
Recent publications
Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
Journal article
Martin RM. et al, (2024), JAMA, 331, 1460 - 1470
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).
Journal article
Lane JA. et al, (2022), BJU Int, 130, 370 - 380
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
Journal article
Hamdy FC. et al, (2020), Health Technol Assess, 24, 1 - 176